№ files_lp_3_process_7_036341
File format: docx
Character count: 4221
File size: 49 KB
Patient information leaflet issued within the NHS in England outlining the routine switch from other SGLT2 inhibitors to dapagliflozin for individuals with heart failure and/or diabetes, including rationale, dosing instructions, safety information, and contact guidance.
Country:
England
Healthcare system:
National Health Service (NHS)
Issuing body:
NHS England
Medicines mentioned:
Dapagliflozin; Forxiga; Empagliflozin; Canagliflozin; Ertugliflozin
Therapeutic class:
SGLT2 inhibitors
Indications:
Heart failure; Diabetes mellitus
Document type:
Patient information leaflet
Subject:
Change of prescribed SGLT2 inhibitor medication
Dosage information:
10mg once daily; 5mg starting dose in patients with liver problems
Target audience:
Patients prescribed SGLT2 inhibitors for heart failure and/or diabetes
Geographical scope:
England
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2014
Region / city:
Australia
Topic:
Pharmaceutical product submission
Document type:
Application for listing
Organization / institution:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
AstraZeneca Pty Ltd
Target audience:
Health professionals, regulatory authorities
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
1 April 2014
Year:
2023
Region / city:
United Kingdom
Topic:
Medicines Optimisation, SGLT2 inhibitors
Document Type:
Protocol
Author:
NHS England
Target Audience:
Healthcare professionals, clinicians, systems involved in diabetes and heart failure treatment
Period of Validity:
Ongoing
Approval Date:
September 25, 2023
Date of Changes:
Not specified
Clinical Area:
Type 2 diabetes, heart failure, chronic kidney disease
Inclusion Criteria:
Patients aged 18 years and older prescribed empagliflozin, canagliflozin, ertugliflozin, or branded dapagliflozin for T2DM and/or HF
Exclusion Criteria:
Severe renal impairment, diabetic ketoacidosis, and other contraindications as per SPC
Background:
Dapagliflozin is now the first-line SGLT2i in England due to cost reduction following patent expiry.
Implementation Date:
Not specified
Post-switch:
No need for additional eGFR monitoring unless clinical concerns arise
Description:
Protocol outlining the process for switching eligible patients from other SGLT2 inhibitors to dapagliflozin for the management of Type 2 diabetes and heart failure in primary care.
Year:
2021
Country:
Australia
Drug:
Dapagliflozin
Brand name:
Forxiga
Dosage form and strength:
Tablet, 10 mg
Sponsor:
AstraZeneca Pty Ltd
Indication:
Chronic kidney disease
Submission type:
Category 1 submission
Requested listing:
Authority Required (Streamlined), General Schedule
Regulatory bodies:
Pharmaceutical Benefits Advisory Committee; Therapeutic Goods Administration
Target population:
Adults with chronic kidney disease with specified eGFR and UACR ranges
Comparator:
Placebo plus standard of care
Intervention:
Dapagliflozin plus standard of care
Clinical claims:
Superior efficacy and non-inferior safety versus standard of care alone
Related indications:
Type 2 diabetes mellitus; heart failure with reduced ejection fraction
Regulatory status date:
Priority review granted 13 November 2020
Year:
2023
Region / city:
United Kingdom
Topic:
Medicines optimisation, SGLT2 inhibitors, diabetes, heart failure
Document type:
Protocol
Organ / institution:
NHS England
Author:
NHS
Target audience:
Clinicians, healthcare providers
Period of validity:
Ongoing
Approval date:
Not specified
Modification date:
Not specified
Year:
2023
Region / city:
United Kingdom
Topic:
Medicine optimisation, diabetes, heart failure, chronic kidney disease
Document type:
Protocol
Organisation:
NHS England
Author:
Not specified
Target audience:
Healthcare professionals
Period of validity:
Ongoing
Approval date:
September 25, 2023
Modification date:
Not specified
Clinical condition:
Type 2 diabetes mellitus, heart failure, chronic kidney disease
Medication:
Dapagliflozin, Empagliflozin, Canagliflozin, Ertugliflozin
Intended use:
Generic dapagliflozin
Switch criteria:
Based on patient needs and clinical appropriateness
Inclusion criteria:
Patients aged 18 years and older currently prescribed certain SGLT2 inhibitors
Exclusion criteria:
History of adverse reactions or specific clinical conditions
Recommended dosage:
10mg once daily, with adjustments for hepatic or renal impairment
Monitoring:
HbA1c, blood tests, signs of infections or DKA
Drug interactions:
Fewer interactions compared to other SGLT2 inhibitors
Patient communication:
Information leaflets, SMS, letters
Post-switch monitoring:
Routine HbA1c checks, watch for DKA
Clinical recommendation:
Consider shared decision-making and patient discussions
References:
NICE guidelines, NHS guidance, formulary recommendations
Year:
2026
Note:
Region / city
Topic:
Wireless LANs, Backoff Procedure
Document type:
Technical submission
Organization / institution:
IEEE
Author:
Yajun Cheng, Xiandong Dong, Tong Xiao, Wein Lin, Xin Zuo, Xu Chen, Tongxin Shu
Context:
This is a technical document addressing proposed comment resolutions for P802.11bn D1.0, specifically related to the backoff procedure after switching back to the BSS primary channel.
Year:
2023
Region / city:
United Kingdom
Topic:
Medicines Optimisation, SGLT2 inhibitors
Document Type:
Protocol
Author:
NHS England
Target Audience:
Healthcare professionals, clinicians, systems involved in diabetes and heart failure treatment
Period of Validity:
Ongoing
Approval Date:
September 25, 2023
Date of Changes:
Not specified
Clinical Area:
Type 2 diabetes, heart failure, chronic kidney disease
Inclusion Criteria:
Patients aged 18 years and older prescribed empagliflozin, canagliflozin, ertugliflozin, or branded dapagliflozin for T2DM and/or HF
Exclusion Criteria:
Severe renal impairment, diabetic ketoacidosis, and other contraindications as per SPC
Background:
Dapagliflozin is now the first-line SGLT2i in England due to cost reduction following patent expiry.
Implementation Date:
Not specified
Post-switch:
No need for additional eGFR monitoring unless clinical concerns arise
Description:
Protocol outlining the process for switching eligible patients from other SGLT2 inhibitors to dapagliflozin for the management of Type 2 diabetes and heart failure in primary care.
Year:
2025
Region / City:
UK
Topic:
Business service switching
Document Type:
Process document
Organisation / Institution:
Federation of Communication Services
Author:
Laura Meakin & Niall Gillespie
Target Audience:
Industry professionals, Retail Communications Providers
Effective Period:
Ongoing
Approval Date:
06.11.2025
Date of Changes:
Not specified
Year:
2025
Region / City:
UK
Theme:
Business switching process
Document Type:
Industry Process Document
Organization / Institution:
FCS (Federation of Communication Services)
Authors:
Laura Meakin & Niall Gillespie
Target Audience:
Retail Communications Providers, Industry Stakeholders
Period of Validity:
Not specified
Approval Date:
Not specified
Last Updated:
06.11.2025
Year:
2025
Region / City:
Prague, Czech
Topic:
Low band carrier aggregation via switching
Document Type:
Discussion/Decision
Organization:
3GPP TSG RAN WG1
Author:
Moderator (Apple)
Target Audience:
Industry professionals and organizations involved in 3GPP technical work
Period of Validity:
N/A
Approval Date:
N/A
Amendment Date:
N/A
Note:
Year
Topic:
Chemistry Education
Document Type:
Educational Guide
Organ / Institution:
OCR
Target Audience:
Teachers, Educational Institutions
Note:
Year
Subject:
Biology
Document Type:
Guide
Institution:
OCR
Target Audience:
Teachers, educators
Year:
2024
Region / City:
Athens, Greece
Topic:
Dynamic waveform switching
Document Type:
Meeting Report
Organization / Institution:
3GPP RAN WG1
Author:
Moderator (InterDigital, Inc.)
Target Audience:
Industry professionals in wireless communications
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Country:
United Kingdom
Healthcare system:
National Health Service
Clinical area:
Cardiology / Stroke prevention
Condition:
Non-valvular atrial fibrillation
Medication:
Apixaban
Medication class:
Direct oral anticoagulant
Purpose:
Switching existing DOAC therapy to apixaban
Target population:
Adults aged 18 years and over with NVAF
Exclusions:
Patients with contraindications to apixaban or indications other than NVAF
Regulatory references:
NICE recommendations, Summary of Product Characteristics
Type of document:
Clinical procedure
Intended users:
Prescribers and pharmacists
Consultation requirement:
Patient consent and clinician consultation
Monitoring requirements:
Renal function and body weight
Geographical scope:
UK clinical practice
Status of apixaban:
Licensed and available as a generic medicine
Note:
Year
Year:
2023
Region / City:
e-Meeting, April 17th – April 26th
Topic:
Dynamic waveform switching
Document Type:
Draft
Organization:
3GPP TSG RAN WG1
Author:
Moderator (InterDigital, Inc.)
Target Audience:
3GPP members, stakeholders in wireless communications
Period of validity:
N/A
Approval Date:
N/A
Amendment Date:
N/A
Year:
2022
Region / city:
Online, February 21 – March 3, 2022
Topic:
MUSIM network switching
Document type:
Technical report
Organization / institution:
Samsung
Author:
Sangyeob Jung (Samsung)
Target audience:
Industry professionals in telecommunications
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Year:
2021
Organization:
3GPP
Technical Group:
TSG RAN WG1
Release:
Rel-17
Meeting:
RAN WG1 #105-e e-Meeting
Meeting period:
May 10–27, 2021
Agenda item:
5.1
Source:
Moderator (China Telecom)
Document type:
Technical meeting contribution
Document purpose:
Discussion
Subject area:
NR uplink transmission, Tx switching, FR1
Related specifications:
TS 38.214
Scope limitations:
Co-located and synchronized network deployment; single TAG for UL carriers
Contributors:
China Telecom, CATT, Qualcomm, vivo, OPPO, ZTE, Huawei, HiSilicon, CMCC
Checkpoints:
May 21, May 25, May 27, 2021
Year:
2023
Region / City:
Global
Theme:
Network Configuration, Routing, VLANs, EtherChannel
Document Type:
Instructor Guide
Organization / Institution:
Cisco
Author:
Cisco Networking Academy
Target Audience:
Instructors and Networking Students
Period of Validity:
Course duration
Approval Date:
2023
Date of Changes:
Not specified
Year:
2021
Region / City:
Global
Topic:
Network Configuration, Routing, VLAN, IPv6
Document Type:
Technical Manual
Organization / Institution:
Cisco
Author:
Cisco Systems
Target Audience:
Networking professionals, Instructors
Period of Validity:
Ongoing
Approval Date:
N/A
Modification Date:
N/A